COX-2 inhibitors may reduce the inhibitory effect on CD8+ T cells through regulating TAMs in tumor immune microenvironment, thus enhancing the T cell-based cytotoxicity and improving the prognosis of HCC patients (Xun et al., 2021). This evidence concerns the gene CD8A and neoplasm.